Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Doctors' views on pharma: part four

To gain a doctor’s perspective on the pharma industry, we interview five healthcare professionals. In part four, we speak with a doctor specialised in geriatric medicine. To coincide with our medical communications focus month, pharmaphorum speaks with five healthcare professionals to...

Articles

Rare disease pricing – is it sustainable?

Doug Paul takes the reins on Siren’s fourth of five rare disease articles and looks into the challenges of orphan drug pricing and reimbursement. Before assessing the future, let us first make sure we understand an important element of the past. In the United States in the...

Articles

Rare disease research: the current and future state

Today is Rare Disease Day – this article, which is the last in the series by Siren Interactive, is an interview between Wendy White and PPMD CEO, Pat Furlong, about the importance of rare disease research. It is estimated that 95 percent of rare diseases do not have an FDA approved therapy. As a result, research is...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital